Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with enfortumab vedotin-ejfv (Padcev, EV) plus pembrolizumab (Keytruda) yields benefits in progression-free ...

默沙东正与辉瑞和安斯泰来合作，针对这一组合进行评估，将其作为尿路上皮癌多阶段广泛临床开发计划的一部分，其中包括两项针对肌层浸润性膀胱癌的3期临床试验正在进行中，即KEYNOTE-B15和KEYNOTE-905试验。

AI点评：迈威生物近一个月获得2份券商研报关注，买入2家，平均目标价为37.87元。

目前，ADC靶点主要集中在HER2、TROP2和Claudin18.2等热门靶点，Nectin-4靶点的研发规模较小，但其是一个经过验证的靶点，Padcev（Enfortumab Vedotinm）是目前第一个也是唯一上市的Nectin-4 ADC药物，虽然其为“first in class”，但其并非完美。相对于晚期尿路上皮癌的良好的 ...

（以下内容从德邦证券《NECTIN-4 ADC临床进展迅速，多个产品积极拓展海外市场》研报附件原文摘录） 迈威生物(688062) 2024上半年业绩：2024H1公司营业收入1.16亿元，同比增长28.42%，主要系药品销售收入0.66亿元，以及9MW3011项目与美国公司独家许可协议确认技术授权 ...

9MW2821, a novel Nectin-4 targeting ADC developed by Mabwell, is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. It's also the ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial ...

9MW2821 是迈威生物自主研发的靶向 Nectin-4 ADC 创新药，是国内同靶点药物中首个开展临床研究的品种，也是全球首款在宫颈癌适应症进入 III 期临床 ...

9MW2821, a novel Nectin-4 targeting ADC developed by Mabwell, is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. It’s also the first ...

Certain types of tumors make up the majority of that 20%, such as melanoma, non-small cell lung cancer, and certain ...